A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Biogen
- 12 Jul 2019 As per European Clinical Trials Database record this trial is Completed in UK.
- 30 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 10 Sep 2018 This trial has been discontinued in UK-MHRA (End date: 2018-03-02).